MarginsXMarginsX
Home › Markets › Health Care › NBTX

Nanobiotix S.A. (NBTX)

NBTX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$28.54
-6.90% on the day
Market cap
$1.5B
Small cap
Revenue · 2025
$36.0M
Prior year not contiguous
Net income · 2025
-$26.5M
-73.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1760854/000176085426000003/0001760854-26-000003-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2025-12-31. Converted from EUR at 0.9048 per USD (today's ECB or Federal Reserve reference rate).

Profile

FieldValue
TickerNBTX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryFrance
IPO year2020
SEC CIK0001760854
SEC industry codePharmaceutical Preparations
Incorporated inFrance

Financials · 2025

LineValue
Revenue$36.0M
Net income-$26.5M
Operating income-$12.0M
Net margin-73.5%
Operating margin-33.2%
Revenue growthNo prior-year revenue to compare
Cash$58.3M
Total assets$74.9M
P/E (computed)Net income was not positive
P/S (computed)40.3×

Reported in EUR; shown in US dollars.

Warning signs

Cash runway
18.9 months
52.8M EUR cash at December 31, 2025
Share count, 1 year
+2.1%
2024-12-31 to 2025-12-31 · +38.8% over 3 years
Going-concern doubt
No
20-F filed March 31, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"Accordingly, Management has determined there is no substantial doubt regarding the Company's ability to continue as a going concern."
20-F 2026-03-31
Cash and burn52.8M EUR cash; operating cash flow -8.4M EUR a quarter.Report 2025-12-31
Shares outstanding48,410,068 (2025-12-31); 47,426,851 a year earlier; 34,875,872 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-05-22
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG SA, Paris La Défense, FrancePCAOB Form AP 2026-05-04
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
32.6M EUR-24.0M EUR-33.4M EUR52.8M EURNo debt tags32.6M EUR20-F 2026-03-31
FY 2024
2024-12-31
-7.2M EUR-68.1M EUR-19.6M EUR49.7M EURNo debt tags-7.2M EUR20-F 2026-03-31
FY 2023
2023-12-31
36.2M EUR-39.7M EUR-12.5M EUR75.3M EURNo debt tags36.2M EUR20-F 2026-03-31
FY 2022
2022-12-31
4.8M EUR-57.0M EUR-37.1M EUR41.4M EURNo debt tags4.8M EUR20-F 2025-04-02
FY 2021
2021-12-31
2.6M EUR-47.1M EUR-29.9M EUR83.9M EURNo debt tags2.6M EUR20-F 2024-04-24
FY 2020
2020-12-31
2.5M EUR-33.6M EUR-27.5M EUR119.2M EURNo debt tags2.5M EUR20-F 2023-04-24
FY 2019
2019-12-31
2.5M EUR-50.9M EUR-41.2M EUR35.1M EURNo debt tags2.5M EUR20-F 2022-04-08
FY 2018
2018-12-31
3.5M EUR-30.3M EUR-26.0M EUR36.2M EURNo debt tags3.5M EUR20-F/A 2021-04-08

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in EUR.

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-05-22
Latest annual report20-F2026-03-31
Latest quarterly / interim
FORM 6-K
6-K2026-11-12

Source: SEC EDGAR submissions feed, 313 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+0.1%
1 month+42.6%
3 months-19.7%
Year to date+32.6%
1 year+51.2%
From 52-week high-44.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
PCRXPacira BioSciences Inc.$36.48+0.05%$1.5B
RAPPRapport Therapeutics Inc.$24.82-5.09%$1.5B
PAHCPhibro Animal Health Corporation$35.02-2.64%$1.4B
KRSAKorsana Biosciences Inc.$32.68+3.25%$1.5B
DMRADamora Therapeutics Inc.$22.50+4.14%$1.4B
LBRXLB Pharmaceuticals Inc$42.99-0.05%$1.4B
SLSSELLAS Life Sciences Group Inc.$7.47-4.96%$1.5B
URGNUroGen Pharma Ltd.$28.10+7.33%$1.4B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier